Fecal Microbiota Transplantation and MicroRNA Regulation in Inflammatory Bowel Diseases
Author Information
Author(s): Olga Brusnic, Boicean Adrian, Fleacă Sorin-Radu, Blanca Grama, Florin Sofonea, Corina Roman-Filip, Iulian Roman-Filip, Adelaida Solomon, Sabrina Bîrsan, Dura Horatiu, Corina Porr, Cristian Adrian, Onisor Danusia Maria
Primary Institution: George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures
Hypothesis
Fecal microbiota transplantation (FMT) can modulate microRNA (miRNA) expression and improve outcomes in inflammatory bowel diseases (IBD).
Conclusion
FMT shows potential clinical benefits by restoring miRNA and antimicrobial peptide balance, aiding in mucosal barrier repair and immune response modulation in IBD.
Supporting Evidence
- FMT can restore microbial diversity, enhancing the gut's resilience against inflammation.
- MiRNAs are linked to immune responses and inflammatory pathways in IBD.
- Certain miRNAs serve as biomarkers for disease progression and therapeutic targets.
- Research is ongoing to understand the specific mechanisms through which FMT exerts its effects.
- Identifying optimal donor characteristics is crucial for the success of FMT.
Takeaway
Fecal microbiota transplantation is like giving your gut a fresh start with healthy bacteria, which can help calm down inflammation and make you feel better if you have gut problems.
Methodology
This review conducted a comprehensive literature search across multiple electronic databases, focusing on studies related to FMT and miRNA in IBD.
Limitations
The review is based on existing literature and may not include all recent studies or clinical trials.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website